OncoSec Featured on KTVU-TV News and in San Francisco Chronicle

OncoSec Featured on KTVU-TV News and in San Francisco Chronicle

Reports Spotlight Use of OMS ElectroImmunotherapy in Clinical Trial for Melanoma

SAN DIEGO, July 24, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, was spotlighted on Oakland television station KTVU-TV on July 20 and in the San Francisco Chronicle on July 18.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The KTVU segment aired during "Channel 2 News at 5." KTVU health and science editor, John Fowler, provided a report on the clinical trial for melanoma currently underway at the University of California-San Francisco (UCSF), under the direction of principal investigator Dr. Adil Daud and in collaboration with OncoSec Medical. Dr. Daud, a patient enrolled in the clinical trial and Punit Dhillon, President and CEO of OncoSec, comment on the OMS ElectroImmunotherapy. The segment notes that OncoSec's therapy is unique because although the electroporation treatment is local, it has shown to have an anti-cancer effect throughout the entire body.

The San Francisco Chronicle article, "Melanoma treatment shows promise at UCSF," describes the features of the OMS ElectroImmunotherapy treatment and highlights clinical results to date, including the positive response of one of the patients enrolled in the clinical trial.

To watch the KTVU-TV report, please visit the following link:
http://www.ktvu.com/videos/lifestyles/health/john-fowler-reports/lZb/

To read the San Francisco Chronicle article in its entirety, please visit the following link:
www.sfgate.com/default/article/Melanoma-treatment-shows-promise-at-UCSF-3714590.php - photo-3202959

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumors and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from traditional cancer treatments. OncoSec's core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine or a chemotherapeutic agent. Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE OncoSec Medical Inc.

Photo:http://photos.prnewswire.com/prnh/20110314/MM64943LOGO
http://photoarchive.ap.org/
OncoSec Medical Inc.

CONTACT: For OncoSec, Amy Chan, Director, Corporate Communications, 1-855-OncoSec (1-855-662-6732), investors@oncosec.com; or For Media and Public Relations, Susan Forman, sforman@investorrelationsgroup.com, IRG, LLC, +1-212-825-3210

Web Site: http://www.oncosec.com


-------
Profile: intent